<SEC-DOCUMENT>0000905148-25-001074.txt : 20250403
<SEC-HEADER>0000905148-25-001074.hdr.sgml : 20250403
<ACCEPTANCE-DATETIME>20250403162842
ACCESSION NUMBER:		0000905148-25-001074
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250401
FILED AS OF DATE:		20250403
DATE AS OF CHANGE:		20250403

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Levy Adam D.
		CENTRAL INDEX KEY:			0002061876
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41551
		FILM NUMBER:		25809945

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY
		STREET 2:		SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acrivon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781174
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825125532
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-207-8979

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-04-01</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001781174</issuerCik>
        <issuerName>Acrivon Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ACRV</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002061876</rptOwnerCik>
            <rptOwnerName>Levy Adam D.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ACRIVON THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>480 ARSENAL WAY, SUITE 100</rptOwnerStreet2>
            <rptOwnerCity>WATERTOWN</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02472</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13315</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>11.26</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-08-15</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>43425</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.7</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-02-28</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>38500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.31</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-02-28</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>74100</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These shares include 10,856 restricted stock units (&quot;RSUs&quot;) from an original grant of 14,475 RSUs on August 16, 2023. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of the original 14,475 RSUs granted, twenty-five percent (25%) vested on August 1, 2024, and the remaining RSUs vest in 3 substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.</footnote>
        <footnote id="F2">Twenty-five percent (25%) of the shares subject to the option vested on August 1, 2024, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.</footnote>
        <footnote id="F3">Twenty-five percent (25%) of the shares subject to the option vested on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.</footnote>
        <footnote id="F4">Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.</footnote>
    </footnotes>

    <remarks>Exhibit List: Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Adam D. Levy</signatureName>
        <signatureDate>2025-04-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>levy_poa.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Sidley Austin LLP
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 158.1pt; margin-left: 158.85pt; font-weight: bold;">POWER OF ATTORNEY</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 158.1pt; margin-left: 159.15pt;">(For Executing Form ID, Forms 3, 4 and 5, and Form 144)</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; margin-right: 5.75pt; margin-left: 5.95pt;">Know all by these presents, that the undersigned hereby constitutes and appoints each of Peter Blume-Jensen, Eric Devroe, Katharine Peterson, and Mary-Alice Miller of Acrivon
      Therapeutics, Inc. (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z13dfcaeaca6a4746838b42f2f0bded97" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 64.55pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 32.95pt; color: #1F1F1F;">(1)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #1F1F1F;">Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the <font style="font-weight: bold; font-style: italic;">&#8220;SEC&#8221;</font>) a Form
                ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16 of the Securities Exchange
                Act of 1934, as amended (the <font style="font-weight: bold; font-style: italic;">&#8220;Exchange Act&#8221;</font>), Rule 144 under the Securities Act of 1933 (<font style="font-weight: bold; font-style: italic;">&#8220;Rule 144&#8221;</font>), or any rule or
                regulation of the SEC;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z7ce1e1c55b394f3d9528740403286fe3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 64.55pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 32.95pt; color: #1F1F1F;">(2)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #1F1F1F;">Execute for and on behalf of the undersigned, in the undersigned&#8217;s capacity as an officer, director, or beneficial owner of more than 10% of a registered class of securities of the Company, any and all reports on
                Form 3, 4, or 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder, and on Form 144 in accordance with Rule 144 (including amendments thereto and joint filing agreements in connection therewith);</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z22716e74e98245e4b846589ccd451dd6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 64.55pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 32.95pt;">(3)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #1F1F1F;">Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Forms 3, 4, or 5, or Form 144 (including amendments thereto and joint filing
                agreements in connection therewith) and timely file such forms with the SEC and any stock exchange, self-regulatory association, or similar authority;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1bd89ab59ee34671b308a574de967977" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 64.55pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 32.95pt;">(4)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div>Enroll the undersigned in the SEC&#8217;s enhanced Electronic Data Gathering, Analysis, and Retrieval system (&#8220;EDGAR Next&#8221;), and serve as an Account Administrator for the undersigned&#8217;s account in EDGAR Next; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z12c1dbbd33ec42b78c138823a5b8f470" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 64.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 32.95pt;">(5)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #1F1F1F;">Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in- fact, may be of benefit to, in the best interest of, or legally required of the undersigned,
                it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in
                the attorney-in-fact's discretion.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; margin-right: 6.45pt; margin-left: 5.9pt; color: #1F1F1F;">The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite,
      necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby
      ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned
      acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section
      16 of the Exchange Act or Rule 144.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; margin-right: 5.75pt; margin-left: 5.9pt; color: #1F1F1F;">This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file reports under
      Section 16(a) of the Exchange Act or Rule 144 with respect to the undersigned&#8217;s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing
      attorneys-in-fact, (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company, and (d) this Power of Attorney is superseded by a new power of attorney regarding the purposes outlined herein at a
      later date.</div>
    <div>&#160;</div>
    <div>
      <div style="margin-right: 5.75pt; margin-left: 41.9pt; color: #1F1F1F;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below. </div>
      <div style="margin-right: 5.75pt; margin-left: 41.9pt; color: #1F1F1F;"> <br>
      </div>
      <div style="margin-right: 5.75pt; margin-left: 41.9pt; color: #1F1F1F;">Date: 4/1/2025</div>
      <div style="margin-right: 5.75pt; margin-left: 41.9pt; color: #1F1F1F;"> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze3fb110d19be4afab9db0f0a72f1f7ec" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 60%; vertical-align: top; padding-bottom: 1px;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 20%; border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(31, 31, 31);">/s/ Adam Levy</div>
          </td>
          <td style="vertical-align: top; width: 20%; padding-bottom: 1px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          <td style="vertical-align: top; width: 20%;" rowspan="1">
            <div style="text-align: center; color: rgb(31, 31, 31);">Signature</div>
          </td>
          <td style="vertical-align: top; width: 20%;" colspan="1" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          <td style="vertical-align: top; width: 20%;" rowspan="1">&#160;</td>
          <td style="vertical-align: top; width: 20%;" colspan="1" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top; padding-bottom: 1px;" colspan="1" rowspan="1">&#160;</td>
          <td style="vertical-align: top; width: 20%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);" rowspan="1">Adam Levy</td>
          <td style="vertical-align: top; width: 20%; padding-bottom: 1px;" colspan="1" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          <td style="vertical-align: top; width: 20%; text-align: center;" rowspan="1">Print Name</td>
          <td style="vertical-align: top; width: 20%;" colspan="1" rowspan="1">&#160;</td>
        </tr>

    </table>
    <div style="margin-right: 5.75pt; margin-left: 41.9pt; color: #1F1F1F;"><br>
    </div>
    <div>&#160;<br>
      <div><br>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
